June 20, 2019 Big hitters eye Sjögren’s syndrome white space Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all interested.
